Colorectal cancer is the third-most-common cancer globally and is associated...
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for metastatic colorectal cancer is dominated by ch...
Market Outlook Biomarker-driven prescribing continues to play an...
Market Outlook Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an important role and are well-......
Colorectal cancer is the third-most-common cancer globally and is associated...
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for metastatic colorectal cancer is dominated by chemother......
The treatment landscape for colorectal cancer is based on chemotherapies and...
The treatment landscape for colorectal cancer is based on chemotherapies and targeted agents, although the latter (e.g., Avastin, Erbitux, Vectibix) are currently confined to the metastatic setti......
Treatment Sequencing provides disease-specific, sequential treatment patterns...
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analys......
Market Outlook The treatment paradigm for second- and subsequent-line...
Market Outlook The treatment paradigm for second- and subsequent-line advanced or metastatic colorectal cancer revolves around targeted agents (such as Erbitux, Vectibix...
DRG Epidemiology's coverage of colorectal cancer comprises epidemiological...
DRG Epidemiology's coverage of colorectal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of c......
Seven premium-priced therapies—Avastin (Roche), Erbitux (Merck KGaA),...
Seven premium-priced therapies—Avastin (Roche), Erbitux (Merck KGaA), Vectibix (Amgen), Zaltrap (Regeneron/Sanofi), Cyramza (Eli Lilly), Stivarga (Bayer HealthCare), and Lonsurf (Servier)&m...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide...
Introduction Colorectal cancer (CRC) affects several thousands of people in...
Introduction Colorectal cancer (CRC) affects several thousands of people in Brazil and Mexico. Once it metastasizes, the only available therapeutic options are prem...
Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga...
Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza—are approved in the...
Colorectal cancer is the third-most-common cancer globally and is associated...
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year OS of Current treatment for metastatic colorectal cancer is dominated by chemotherapy regimens in combi......
Several therapies are available for treatment of second- and subsequent-line...
Several therapies are available for treatment of second- and subsequent-line advanced/ metastatic colorectal cancer that have a positive effect of patient survival, but none of them are able......
How Will Physician and Payer Attitudes and Decisions Shape this Market? The...
How Will Physician and Payer Attitudes and Decisions Shape this Market? The treatment of metastatic colorectal cancer (mCRC) is increasingly driven by patients’ RAS mutational sta......
How Receptive Are Physicians and Payers to Premium-Priced Emerging Therapies in...
How Receptive Are Physicians and Payers to Premium-Priced Emerging Therapies in This Underserved Market? Patients with advanced/metastatic colorectal cancer (mCRC) typically r......
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal...
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (......
